EUVIMEDEUVIMED entdecken
Crossref

HER2 immunoreactivity in advanced non-p53abn endometrial carcinoma: Association with clinical features, prognosis, and molecular characteristics

Yining Zhen, Yinbo Xiao, Yang Zhou, Longyun Chen, Junyi Pang, Xiaohua Shi, Zhiyong Liang

Pathology - Research and Practice · 2026

DOI: 10.1016/j.prp.2025.156304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Yining Zhen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730,…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Tumor Suppressor Protein p53, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an emerging therapeutic target in endometrial carcinoma (EC). Current guidelines recommend routine HER2 testing for p53 abnormal (p53abn) tumors, potentially underestimating its value in non-p53abn cases. This study aimed to assess the incidence and clinical relevance of HER2 immunoreactivity in advanced non-p53abn EC. METHODS: HER2 immunohistochemistry and next-generation sequencing were performed in 128 advanced EC patients. Clinicopathological features, survival, and molecular alterations were compared according to HER2 immunoreactivity. RESULTS: Of all patients, 18.8 % were HER2 2 + /3 + , 28.9 % were HER2 1 + , and 52.3 % were HER2 0. Molecular classification included 1.6 % POLE mutant, 35.2 % mismatch repair-deficient/ microsatellite instability-high, 29.7 % p53abn, and 33.6 % no specific molecular profile (NSMP). In the non-p53abn group, HER2 3 + was less frequent than in the p53abn group, whereas the frequencies of HER2 2 + and 1 + did not differ significantly between the two groups. In non-p53abn patients, HER2 2 + /3 + occurred most frequently in clear cell carcinoma (CCC, 6/11, 54.5 %) and was associated with adnexal metastasis (2 +/3 + vs. 1 +, 66.7 % vs. 15.4 %, P < 0.05). No survival differences were observed among non-p53abn patients by HER2 immunoreactivity, however, within the NSMP subgroup, both overall and progression-free survival were worse in HER2 2 + /3 + compared with 1 + (log-rank P < 0.05). In non-p53abn ECs, KRAS mutations were significantly less frequent in HER2 2 + /3 + group (2 +/3 + vs. 1 +, 6.7 % vs. 46.2 %, P < 0.05). CONCLUSIONS: HER2 2 + /3 + immunoreactivity was detected in 16.7 % of advanced non-p53abn EC, particularly enriched in CCC. These findings highlight the potential clinical significance of HER2 testing in non-p53abn patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsErb-b2 Receptor Tyrosine KinasesTumor Suppressor Protein p53Biomarkers, TumorHumansFemaleMiddle AgedAgedPrognosisImmunohistochemistryAdultAged, 80 and overMutation

Stichwörter der Autor:innen

Endometrial carcinomaHER2Molecular subtypeNon-p53abn

Substanzen

Erb-b2 Receptor Tyrosine KinasesTumor Suppressor Protein p53Biomarkers, TumorERBB2 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. Electronic address: shixh@pumch.cn.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. Electronic address: liangzy@pumch.cn.

Zitieren

APA

Zhen, Y., Xiao, Y., Zhou, Y., Chen, L., Pang, J., Shi, X., & Liang, Z. (2026). HER2 immunoreactivity in advanced non-p53abn endometrial carcinoma: Association with clinical features, prognosis, and molecular characteristics. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156304

Vancouver

Zhen Y, Xiao Y, Zhou Y, Chen L, Pang J, Shi X, et al. HER2 immunoreactivity in advanced non-p53abn endometrial carcinoma: Association with clinical features, prognosis, and molecular characteristics. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2025.156304

BibTeX
@article{Zhen2026,
  author = {Zhen, Yining and Xiao, Yinbo and Zhou, Yang and Chen, Longyun and Pang, Junyi and Shi, Xiaohua and Liang, Zhiyong},
  title = {HER2 immunoreactivity in advanced non-p53abn endometrial carcinoma: Association with clinical features, prognosis, and molecular characteristics},
  journal = {Pathology - Research and Practice},
  year = {2026},
  doi = {10.1016/j.prp.2025.156304}
}
Kostenlos starten →